CLINICAL STUDY. From the 1 Cardiovascular Center, Seoul National University Hospital, Seoul,
|
|
- Todd Hicks
- 5 years ago
- Views:
Transcription
1 CLINICAL STUDY The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial Jung-Won Suh, 1,2 MD, Seung-Pyo Lee, 1 MD, KyungWoo Park, 1 MD, Hyun-Jae Kang, 1 MD, Bon-Kwon Koo, 1 MD, Young-Seok Cho, 2 MD, Tae-Jin Youn, 2 MD, In-Ho Chae, 2 MD, Dong-Ju Choi, 2 MD, Seung-Woon Rha, 3 MD, Jang-Ho Bae, 4 MD, Taek-Geun Kwon, 4 MD, Jang-Whan Bae, 5 MD, Myeong-Chan Cho, 5 MD and Hyo-Soo Kim, 1 MD Summary It is not clear if anti-restonotic effect of cilostazol is consistent for different types of drug-eluting stents (DES). The purpose of this study was to compare the anti-proliferative effect of cilostazol between DAT and TAT with consideration of confounding influences of DES type. Nine hundred and fifteen patients were randomized to either dual antiplatelet therapy (DAT; aspirin and clopidogrel) or triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol) in the previous CILON-T trial. After excluding 70 patients who received both or neither stents, we analyzed 845 patients who received exclusively PES or ZES, and compared in-stent late loss at 6 months between both antiplatelet regimens (DAT versus TAT). Baseline angiographic and clinical characteristics were similar between the DAT (656 lesions in 425 patients) and the TAT group (600 lesions in 420 patients). The 6-month follow-up angiography was completed in 745 patients (88.2%). Quantitative coronary angiography showed that TAT significantly reduced in-stent late loss (DAT 0.62 ± 0.62 mm versus TAT 0.54 ± 0.49 mm, P = 0.015). Stent type, diabetes or lesion length did not interact with difference of late loss. However, reduction of late loss by cilostazol did not lead to a significant reduction in the rate of target lesion revascularization (TLR) (DAT 7.8% versus TAT 6.9%, P = 0.69) due to a nonlinear relationship found between late loss and TLR. The TAT group showed less in-stent late loss as compared to the DAT group. This was consistently observed regardless of DES type, lesion length, or diabetic status. However, reduction of late loss by cilostazol did not lead to a significant reduction in TLR. (Int Heart J 2017; 58: ) Key words: Cilostazol, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Restenosis C ilostazol is a selective phosphodiesterase (PDE) 3 inhibitor that is commonly prescribed in patients with peripheral artery disease. It reduces restenosis of bare metal stents and drugeluting stents (DES) after percutaneous coronary intervention (PCI) as a result of its anti-proliferative effect. 1) It also intensified platelet inhibition in patients who showed high post-treatment platelet reactivity despite conventional dual antiplatelet therapy (DAPT). 2-4) Previous studies showed the benefit of cilostazol in specific subgroups, such as diabetic patients and those with long coronary lesions. 5-7) However, it is not clear if these results can be extrapolated to the general population. The CILON-T trial was a prospective, randomized trial that compared the efficacy of dual antiplatelet therapy (DAT) (i.e., aspirin, clopidogrel) and triple antiplatelet therapy (TAT) (i.e., aspirin, clopidogrel, and cilostazol) in patients who underwent drug-eluting stent (DES) implan- From the 1 Cardiovascular Center, Seoul National University Hospital, Seoul, 2 Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, 3 Cardiovascular Center, Korea University Guro Hospital, Seoul, 4 Heart Center, Konyang University Hospital, Daejon and 5 Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea. This study was supported by a grant from the SNUBH Research Fund ( ) and a grant from the Clinical Research Center for Ischemic Heart Disease, Seoul, Republic of Korea (0412-CR ). Address for correspondence: Hyo-Soo Kim, MD, Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, 101 Daehang-no, Chongno-gu, Seoul , Korea. hyosoo@snu.ac.kr Received for publication July 18, Revised and accepted January 13, Released in advance online on J-STAGE November 8, doi: /ihj All rights reserved by the International Heart Journal Association. 853
2 854 Suh, ET AL IntHeartJ November patients eligible for trial Withdrawal at patient request (n =5) Withdrawal at clinician s judgment (n = 33) Failed percutaneous coronary intervention (n =7) 915 patients enrolled for final analysis Neither PES nor ZES (n = 64) Both PES and ZES (n =6) DAT (n = 425) TAT (n = 420) PES 334 lesions/218 patients ZES 322 lesions/207 patients PES 327 lesions/230 patients ZES 273 lesions/190 patients Follow-up angiography at 6 months (n = 745, 88.2%) PES 278 lesions/183 patients ZES 294 lesions/189patients PES 293 lesions/205 patients ZES 247 lesions/168 patients Figure 1. Study flow. tation. 2,8) In this study, we analyzed the effect of cilostazol on restenosis after DES implantation by using angiographic analysis to compare late loss in patients enrolled in the CILON-T trial. Analyses were stratified by the type of antiplatelet regimen (DAT versus TAT) and the type of DES, the paclitaxel-eluting stent (PES, TAXUS Express2, Boston Scientific Corporation) versus the zotarolimuseluting stent (ZES, Endeavor Sprint, Medtronic). Methods Patients: The CILON-T trial was a prospective, openlabel randomized trial that took place at five centers in South Korea: the Seoul National University Hospital, Seoul National University Bundang Hospital, Korea Guro Hospital, Konyang University Hospital, and Chungbuk National University Hospital. Patients were enrolled between September 2006 and June ,8) All patients gave written informed consent, and the institutional review boards at the five centers approved this study. The design of the CILON-T trial has been published elsewhere, and the full protocol is registered at (NCT ). 8) Briefly, a total of 960 consecutive patients who were implanted with a DES were randomized into two groups to receive either DAT (aspirin and clopidogrel) or TAT (aspirin, clopidogrel, and cilostazol) (Figure 1). Among the initially randomized patients, five patients withdrew consent, seven patients failed to implant DES for the target lesion, and 33 patients withdrew from the study by the duty physician s judgment for several reasons, which included high risk of significant bleeding in the near future, and a planned operation that needed antiplatelet agent modification or discontinuation. In the present study, we analyzed patients (n = 845) treated with either the PES or the ZES after excluding 70 patients who were treated with both stents (n =6)orneither stent (n = 64). In the DAT group, PESs were implanted at 334 lesions in 218 patients whereas ZESs were implanted at 322 lesions in 207 patients. In the TAT group, PESs were implanted at 327 lesions in 230 patients, whereas ZESs were implanted at 273 lesions in 190 patients. Follow-up angiography was done in 745 patients (88.2%; DAT n = 372, TAT n = 373) 6 months after stent implantation. Study endpoints and clinical follow-up: The primary endpoint of this study was in-stent late loss at 6 months. The secondary endpoints included in-segment late loss and restenosis rate (diameter stenosis > 50%), target lesion revascularization (TLR), and the occurrence of a major adverse cardiovascular event (MACE), including cardiac death, a nonfatal myocardial infarction, clinically driven TLR, and ischemic stroke at 6 months. Other secondary endpoints were all-cause death and stent thrombosis at 6 months. Safety assessment included bleeding complications according to the Thrombolysis In Myocardial Infarction (TIMI) criteria during the treatment period. 9) The cause of death was regarded as cardiovascular unless there was documented evidence for a clear, noncardiovascular cause. Myocardial infarction (MI) was defined as a creatinine kinase myocardial band > 3 times
3 IntHeartJ November 2017 CILOSTAZOL AND DRUG-ELUTING STENT RESTENOSIS 855 upper limit of normal. Ischemic stroke was defined as a new focal neurologic deficit of vascular origin lasting at least 24 hours that was proven to be non-hemorrhagic by either computed tomography or magnetic resonance imaging scanning. TLR was considered clinically driven when it was associated with typical symptoms upon clinical assessment, typical signs during the stress test, or > 70% stenosis on angiographic follow-up. Stent thrombosis was defined as any of the following: angiographic documentation of occlusion of the target lesion associated with an acute ischemic event, irrespective of the presence of visible thrombi on the angiograph, unexplained sudden death, and MI not clearly relevant to another coronary lesion. Follow-up: Repeat coronary angiography was performed at 6 months, or earlier if indicated. Clinical follow-up visits were scheduled 1, 3, 6, and 12 months after the procedure. The investigators followed the patients, either by office visit or by telephone as necessary. Drug compliance and adverse events were assessed during each visit for clinical follow-up. QCA analysis: Pre-procedure, post-procedure, and follow-up angiograms obtained after intracoronary nitroglycerin administration were submitted to the core analysis center (Seoul National University Hospital, Seoul, Korea). Digital angiograms were analyzed using an automated edge detection system (CASS II, Pie Medical, Maastricht, Netherlands). Quantitative coronary angiographic measurements were obtained both in-stent and insegment (stented segment and margins 5 mm proximal and distal to the stent). In-segment late loss was calculated by using the maximal regional late loss method. 10,11) Statistical analysis: Analysis of the two groups (DAT and TAT) was performed according to the intention-to-treat principle. Continuous variables are presented as the mean ± standard deviation. Means were compared using Student s unpaired t-test. Categorical variables are presented as numbers or percentages and were compared using either Chi-square Analysis or Fisher s Exact Test. A general linear model (analysis of covariance; ANCOVA) was applied to quantify the impact of cilostazol on late loss while controlling the effect of statin type. Multiple linear regression and logistic regression were used to assess the effect of DES on each outcome variable. Prespecified subgroup analysis per stent type, lesion length, or diabetic status was performed to compare the primary endpoint between the two groups by using a linear regression method. A P-value < 0.05 was considered statistically significant. A receiver operating characteristic (ROC) curve analysis was used to determine if in-stent late loss differed between patients with and without TLR after PCI. 12,13) Results Baseline characteristics: There were no significant differences between the DAT and TAT groups for the baseline clinical characteristics except for the prescription rate of angiotensin II receptor blockers at discharge after the index procedure (Table I). Angiographic outcomes: The two groups had similar baseline and post-procedural QCA characteristics (Table II). Follow-up angiography was performed in 88.8% of individuals from the DAT group and in 87.5% of individuals from the TAT group (P = 0.61) (Table III). At 6 months, TAT significantly reduced in-stent late loss (0.62 ± 0.51 mm DAT versus 0.54 ± 0.49 mm TAT, P = 0.015) and marginally reduced in-segment late loss (0.40 ± 0.49 mm DAT versus 0.35 ± 0.47 mm TAT, P = 0.10). There was a significant difference in the in-stent late loss between the DAT and the TAT group after controlling the effect of stent type (0.615 [ ] mm versus [ mm]; P = 0.046). Thus, the instent (P = 0.016) and in-segment minimum lumen diameters were larger in the TAT group than in the DAT group (P = 0.094). Target lesion revascularization was performed in 62 patients (DAT 33 patients (7.8%) versus TAT 29 patients (6.9%), P = 0.69) of 103 lesions (DAT 57 lesions (8.7%) versus TAT 46 lesions (7.7%, P = 0.54)). In the analysis of the PES and the ZES, the trend of late loss reduction by cilostazol was consistently observed for both the PES (0.53 ± 0.49 mm in DAT versus 0.48 ± 0.45 mm in TAT, P = 0.22) and the ZES (0.70 ± 0.52 mm in DAT versus 0.62 ± 0.51 mm in TAT, P = 0.075). The data from the linear regression analysis using antiplatelet therapy group (DAT versus TAT), stent type, diabetic status, and lesion length as covariates showed that TAT was significantly associated with decreased late loss, which was independent of stent type, diabetic status, or lesion length compared to DAT (Δ in-stent late loss: DAT- TAT, 95% CI = , P = 0.015). Prespecified subgroup analysis demonstrated that the difference in in-stent late loss between the two groups (DAT versus TAT) did not interact with the type of DES (PES versus ZES, P = 0.62), diabetic status (P = 0.68), or lesion length (P = 0.32) (Figure 2). Association between in-stent late loss and TLR: Among patients who underwent TLR, no difference in late loss was detected between the DAT group and the TAT group (1.40 ± 0.76 mm DAT versus 1.33 ± 0.70 mm TAT, P = 0.68). In the ROC curve analysis, in-stent late loss was able to distinguish patients with TLR from those without (AUC = 0.92, 95% confidence interval , P < ). A late loss of 1.13 mm was identified as the optimal cutoff value to predict TLR, providing a sensitivity of 83.3%, a specificity of 92.1%, a positive predictive value of 40.3%, and a negative predictive value of 98.8%. Figure 3 represents the actual plots of in-stent late loss for all lesions and lesions undergoing TLR in both the DAT and TAT groups. The distribution of late loss was down-shifted in the TAT group, more than in the DAT group. However, both groups had a similar number of patients showing greater late loss than the cutoff value, 1.13 mm (14.0% in the DAT group versus 10.9% in the TAT group, P = 0.18), leading to no difference in the TLR rates. When we analyzed the cumulative incidence of TLR as defined by increments of in-stent or in-segment late loss (Figure 4A, B), the probability of TLR sharply increased at the point of late loss around 1.5 mm in both the DAT and TAT groups. Clinical and angiographic predictors of TLR: The significant predictors for TLR were diabetes mellitus, current
4 856 Suh, ET AL IntHeartJ November 2017 Table I. Baseline Clinical Characteristics DAT (n = 425) TAT (n = 420) P Age, years 62.9 ± ± Male, n (%) 297 (70.0) 287 (69.4) 0.46 BMI, kg/m ± ± Medical history, n (%) Hypertension 286 (67.3) 270 (64.3) 0.38 Diabetes mellitus 135 (31.8) 151 (36.0) 0.22 Dyslipidemia 162 (38.1) 183 (43.6) 0.11 PCI 35 (8.2) 29 (6.9) 0.52 CABG 11 (2.6) 8 (1.9) 0.64 Current smoker, n (%) 98 (23.1) 103 (24.5) 0.55 Acute coronary syndrome, n (%) 225 (52.9) 206 (49.0) 0.61 Laboratory results Hematocrit, % 40.0 ± ± Total cholesterol, mg/dl ± ± Triglyceride, mg/dl ± ± LDL, mg/dl ± ± HDL, mg/dl 43.7 ± ± Creatinine, mg/dl 1.05 ± ± Medication at discharge Statin, n (%) 0.33 Atorvastatin 214 (50.4) 217 (51.7) Rosuvatatin 207 (48.7) 201 (47.9) Beta-blocker, n (%) 221 (52.7) 215 (51.8) 0.84 ACE inhibitor, n (%) 108 (25.8) 96 (23.1) 0.38 ARB, n (%) 91 (21.7) 66 (15.9) 0.03 Calcium channel blocker, n (%) 117 (27.9) 105 (25.3) 0.43 Nitrate, n (%) 174 (41.5) 161 (38.8) 0.44 Proton pump inhibitor, n (%) 8 (1.9) 11 (2.7) 0.50 DAT indicates dual antiplatelet therapy; TAT, triple antiplatelet therapy; BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LDL, low density lipoprotein; HDL, high density lipoprotein; ACE, angiotensin-converting enzyme; and ARB, angiotensin II receptor blocker. Table II. Baseline Angiographic Characteristics DAT (n = 656 lesions) TAT (n = 598 lesions) P Involved coronary artery 0.06 Left main, n (%) 9 (1.4) 11 (1.8) Left anterior descending, n (%) 284 (43.3) 275 (46.0) Left circumflex, n (%) 165 (25.2) 171 (28.6) Right coronary 198 (30.2) 141 (23.6) ACC/AHA type B2/C, % Bifurcations, % Ostial lesions, % Calcified lesions, % Thrombotic lesion, % QCA Before procedure Reference diameter, mm 2.91 ± ± Minimal luminal diameter, mm 0.82 ± ± Lesion length, mm 22.7 ± ± After procedure MLD, in-segment 2.23 ± ± MLD, in-stent 2.55 ± ± DAT, dual antiplatelet therapy; TAT, triple antiplatelet therapy; QCA, quantitative coronary angiography; and MLD, minimal luminal diameter. smoking, lesion length, and ZES, based on the multivariate analysis, which included clinical factors (i.e., age 70 years, sex, diabetes mellitus, smoking status, and TAT versus DAT), as well as angiographic parameters, including PES versus ZES, lesion length, and residual stenosis after stenting (Table IV). TAT, as compared to DAT, was not a
5 IntHeartJ November 2017 CILOSTAZOL AND DRUG-ELUTING STENT RESTENOSIS 857 Table III. Follow-Up Quantitative Coronary Angiography DAT (n = 572 lesions) TAT (n = 540 lesions) P Reference diameter, mm In-segment 2.72 ± ± In-stent 2.78 ± ± MLD, mm In-segment 1.84 ± ± In-stent 1.94 ± ± Late loss, mm In-segment 0.40 ± ± In-stent 0.62 ± ± Diameter stenosis, % In-segment 17.8 ± ± In-stent 14.4 ± ± MLD, minimal luminal diameter. Mean (95% CI) In-stent late loss P P for interaction Overall ( ) Stent type 0.62 PES ( ) 0.22 ZES ( ) DM 0.68 DM ( ) 0.25 Non-DM ( ) Lesion length 0.32 < 28mm ( ) mm ( ) mm mm 0.2mm DAT better TAT better Figure 2. Difference in in-stent late loss (Δ in-stent late loss: DAT-TAT) between the dual and triple antiplatelet therapy groups by clinical and angiographic characteristics. significant prognostic factor in the analysis (OR = 0.86, 95% CI = , P = 0.54). Clinical and safety outcomes: Thirty-one patients (7.4%) in the TAT group stopped cilostazol due to side effects, such as headache, palpitation, rash or gastrointestinal side effects. The frequency of MACE did not differ between the DAT and TAT groups (DAT 8.9% versus TAT 8.1%, P = 0.71) at the 6-month follow-up. There were also no differences in bleeding complications between the two groups. Table V summarizes the clinical outcomes for the DAT and TAT groups. Discussion In the present analysis, we found that the TAT failed to reduce TLR, although it significantly reduced in-stent late loss when compared to DAT for those with either a PES or a ZES. We also identified several risk factors that could predict TLR at 6 months after PCI. Antirestenotic effect of cilostazol: Previous studies showed that the antirestenotic effect of cilostazol was consistent both for bare metal stents and DESs. In the CREST trial, treatment with cilostazol reduced in-stent late loss by approximately 14% compared to placebo (0.91 ± 0.60 mm versus 1.06 ± 0.69 mm, P = 0.01) in patients implanted with bare metal stents. It also signifi-
6 858 Suh, ET AL IntHeartJ November 2017 cantly reduced the in-stent binary restenosis rate (20.85% versus 31.44%, P = 0.01). 1) During the DES era, cilostazol therapy achieved an approximate 18% reduction in instent late loss compared to placebo in patients implanted with a ZES (0.56 ± 0.55 mm versus 0.68 ± 0.59 mm, P = 0.045). However, it was not associated with a decreased rate of target vessel revascularization (16% versus 16%, P = 0.90). 14) Figure 3. Distribution of in-stent late loss stratified per antiplatelet strategy. TAT indicates all the patients who received triple antiplatelet therapy; TLR (+) TAT, the patients who underwent target lesion revascularization (TLR) and received TAT; DAT, all the patients who received dual antiplatelet therapy; and TLR (+) DAT: the patients who underwent TLR and received DAT. Discrepancy between late loss and TLR: This study showed that there was an association between the degree of late loss and TLR and that a late loss of 1.13 mm was identified as the optimal cutoff value to predict TLR. The distribution of late loss was down-shifted more in the TAT group than in the DAT group. However, we did not find that greater reduction of late loss led to significantly lower TLR rates in this analysis due to the insignificant difference in the actual number of patients having larger in-stent late loss than the cutoff value (1.13 mm) between the DAT (14.0%) and TAT (10.9%) groups (P = 0.18). This means that cilostazol could not reduce the number of patients who were potential candidates for TLR. A previous study suggested that coronary stenting results in large lumens with room to accommodate up to ~0.5 to 0.65 mm of neointimal tissue (angiographic analysis segment late loss) before the likelihood of clinical restenosis exceeds 5%-10%. 10) Most of late loss reduction in the TAT group compared to the DAT group was modest, and it was seen in the relatively flat portion of the association curve between TLR and late loss, which might result in no difference in TLR between the DAT and TAT groups. In addition, the insignificant and milder reduction of insegment late loss by cilostazol may contribute to the absence of a difference in the rate of TLR between the DAT and TAT groups. The anti-proliferative effect of cilostazol in patients with high risk features: Previous studies suggested that cilostazol therapy could be beneficial in terms of resteno- Figure 4. The probability of TLR according to the increment of late loss. A: In-stent late loss, B: In-segment late loss. Table IV. Clinical and Angiographic Predictors of TLR at the Six-Month Follow-Up Odds Ratio 95% confidence interval P Current smoker (versus non-smoker) ZES (versus PES) Lesion length (every increase in 1 mm) < Diabetes mellitus ZES, zotarolimus-eluting stent; and PES, paclitaxel-eluting stent.
7 IntHeartJ November 2017 CILOSTAZOL AND DRUG-ELUTING STENT RESTENOSIS 859 Table V. Clinical Outcomes at the Six-Month Follow-Up DAT (n = 425) TAT (n = 420) P MACE (%) 38 (8.9) 34 (8.1) 0.71 Cardiac death 0 3 (0.7) 0.25 Nonfatal MI 3 (0.7) 3 (0.7) 1.0 Ischemic stroke 5 (1.2) 5 (1.2) 1.0 TLR 33 (7.8) 29 (6.9) 0.69 Bleeding events (%) 0.51 TIMI criteria, major 1 (0.2) 2 (0.5) TIMI criteria, minor 1 (0.2) 0 MACE, major adverse cardiovascular event; MI, myocardial infarction; TLR, target lesion revascularization; and TIMI, thrombolysis in myocardial infarction sis, especially in patients with high-risk features, such as diabetes mellitus or long lesions. 5-7) However, the difference in in-stent late loss between the two groups did not interact with the type of DES (PES versus ZES), diabetic status, or lesion length in this study. This suggests that the anti-proliferative effect of cilostazol is not influenced by specific clinical or angiographic characteristics. Risk factors of TLR in the 1st generation of DES: Multivariate analysis confirmed that smoking, the use of ZES (versus PES), lesion length, and diabetes mellitus were predictors of TLR. The control of classic risk factors and the selection of DESs that have good angiographic profiles may be better for preventing TLR than additional pharmacologic intervention. If we consider common side effects, such as headache, gastrointestinal symptom, palpitation and tachycardia, which are not tolerable to a considerable number of patients, 15,16) the addition of cilostazol for the purpose of preventing target lesion revascularization should be reserved. Study limitations: First, this study is a subgroup analysis of a randomized, controlled trial although the analysis was prespecified. Second, the number of patients was relatively small for the comparison of clinical outcomes. The reduction of late loss by cilostazol was consistently observed regardless of stent type, diabetic status, or lesion length. The actual distribution of late loss in all lesions was down-shifted in the TAT group more than in the DAT group; thus, we could acknowledge the anti-proliferative effect of cilostazol. A study including a larger numbers of patients may enable us to translate sensitive variables, like difference in late loss, into less sensitive variables, like difference in clinical outcome. Third, only two types of the first generation DESs were compared in this study. Conclusion Cilostazol has a modest, consistent anti-proliferative effect, regardless of the type of DES, lesion length, or diabetic status. However, such an anti-proliferative effect does not lead to a significant reduction in the rate of TLR, due to the nonlinear relationship between angiographic late loss and TLR. Acknowledgment The authors appreciate statistical advice of Dr. Si- Hyuck Kang and Dr. Yun Gi Kim. We also thank Ms. Tae-Eun Kim (research coordinator), Mr. Jiyeob Lee (senior cardiovascular technologist), Ms. Sunyoung Yoo (QCA researcher) and Ms. Eunjung Park (QCA researcher) for their cordial support. Disclosures Conflicts of interest: None. References 1. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al; Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazolbased triple antiplatelet therapy ON ischemic complication after drug-eluting stent implantation) trial. J Am Coll Cardiol 2011; 57: Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: Fu Q, Yokoyama N, Takada K, Ishikawa S, Isshiki T. Comparison of platelet P2Y(12) ADP receptor-mediated pathway in triple versus dual antiplatelet therapy as assessed by VASPphosphorylation in Japanese patients undergoing coronary stenting. Int Heart J 2010; 51: Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients withdiabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008; 51: Lee SW, Park SW, Kim YH, et al. DECLARE-Long Study Investigators. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007; 100: Lee SW, Chun KJ, Park SW, et al. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 2010; 105: Lee SP, Suh JW, Park KW, et al. Study design and rationale of Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T) study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials 2010; 11: Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115: Ellis SG, Popma JJ, Lasala JM, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stentimplantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: Nomura T, Suzuki N, Takamura S, Kyono H, Kozuma K. Three-
8 860 Suh, ET AL IntHeartJ November 2017 year clinical and angiographic outcomes after everolimus-eluting stent implantation in patients with a History of coronary artery bypass grafting. Int Heart J 2016; 57: Huang J, Zhao S, Chen Z, Zhang S, Lu M. Contribution of electrocardiogram in the differentiation of cardiac amyloidosis and nonobstructive hypertrophic cardiomyopathy. Int Heart J 2015; 56: Shiino K, Sugimoto K, Yamada A, et al. Usefulness of right ventricular basal free wall strain by two-dimensional speckle tracking echocardiography in patients with chronic thromboembolic pulmonary hypertension. Int Heart J 2015; 56: Lee SW, Park SW, Kim YH, et al; DECLARE-LONG II Study Investigators. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011; 57: Kwon BJ, Lee SH, Kim DB, et al. A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease. J Atheroscler Thromb 2015; 22: Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e89s-e119s. (Review)
Abstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationOptimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More information1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.
Midterm Clinical Outcomes of Insulin Requiring Diabetes Mellitus versus Non-insulin Dependent Diabetes Mellitus in Acute Myocardial Infarction Patients in Drug Eluting Stent Era : Insight from Korea Acute
More informationCilostazol: Triple Benefits More is Better!
Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,
More informationImpact of Lesion Length on Chronic Total Occlusion Intervention Outcomes
Impact of Lesion Length on Chronic Total Occlusion Intervention Outcomes Seung-Woon Rha, Amro Elnagar, Byoung Geol Choi, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim,
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationTrial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationJournal of the American College of Cardiology Vol. 57, No. 3, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 3, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.631
More informationHyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018
Six-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE): a randomized, openlabel, multicenter trial
More informationMedicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent Ju-Youn Kim,
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationDifferences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea
REVIEW DOI 10.4070 / kcj.2009.39.8.297 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology Differences in Clinical Outcomes Between Patients With ST-Elevation
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation
1420 KIM HL et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Ischemic Heart Disease Cilostazol Eliminates Adverse Smoking Outcome
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationA New Strategy for Discontinuation of Dual Antiplatelet Therapy
Journal of the American College of Cardiology Vol. 60, No. 15, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.043
More informationIncidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction Sungmin Lim, Yoon Seok Koh, Hee Yeol Kim, Ik Jun Choi, Eun Ho Choo, Jin Jin Kim, Mineok
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationSeung-Woon Rha, MD, PhD FACC, FAHA, FESC, FSCAI, FAPSIC. Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea.
Controversies in Acute Myocardial Infarction - Is Early Statin Therapy is Beneficial in all Patients?- : Insights from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha, MD, PhD FACC, FAHA,
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationLong-term outcomes of simple crossover stenting from the left main to the left anterior descending coronary artery
ORIGINAL ARTICLE Korean J Intern Med 2014;29:597-602 Long-term outcomes of simple crossover stenting from the left main to the left anterior descending coronary artery Ho-Myung Lee 1,*, Chang-Wook Nam
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationDECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.
DECISION-CTO Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Seung-Jung Park, MD., PhD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationDivision of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationSuccessful Percutaneous Coronary Intervention in a Centenarian Patient With Acute Myocardial Infarction
Case Report Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Successful Percutaneous Coronary Intervention in a Centenarian Patient With Acute Myocardial Infarction Ki Hong Lee, MD,
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationAcute and Subacute Stent Thrombosis in a Patient With Clopidogrel Resistance: A Case Report
CSE REPORT DOI 10.4070 / kcj.2009.39.10.434 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology Open ccess cute and Subacute Stent Thrombosis in a Patient With
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationResearch Article. Open Access
Journal of Geriatric Cardiology (2015) 12: 208 217 2015 JGC All rights reserved; www.jgc301.com Research Article Open Access Comparison of clinical outcomes between culprit vessel only and multivessel
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationDECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators
DECISION - CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients with ChronIc Total OccluSION Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators Asan Medical
More informationDIAMOND Study Investigators
Seung-Ho Hur, Wooyeong Jang, Jang-Whan Bae, Dong-Ju Choi, Young-Keun Ahn, Jong-Sun Park, Rak-Kyeong Choi, Dong-Hoon Choi, Joon-Hong Kim, Kyoo-Rok Han, Hun-Sik Park, So-Yeon Choi, Jung-Han Yoon, Hyeon-Cheol
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Park S-J, Ahn J-M, Kim Y-H, et al. Trial of everolimus-eluting
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationThe Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation
ORIGINAL ARTICLE DOI 10.4070 / kcj.2010.40.1.10 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2010 The Korean Society of Cardiology Open Access The Effect of Cilostazol on Stent Thrombosis
More informationMethods. Study patients
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study Yaling Han,
More informationClinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents
ORIGINAL ARTICLE Korean J Intern Med 2013;28:72-80 Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents Jang-Won
More informationDrug eluting stents (DES) have decreased
JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 11, 1 1 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jcmg.1.. BRIEF REPORT OCT-Verified
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationEfficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation
ORIGINAL ARTICLE DOI 10.4070 / kcj.2009.39.5.190 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology Efficacy of Triple Anti-Platelet Therapy Including Cilostazol
More informationTriple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
1034 Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis HONG ZHOU, XIAO-LING FENG, HONG-YING ZHANG, FEI-FEI XU and
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationReview Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationCoronary drug-eluting stents (DES) were first approved
Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax
More information